This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (17)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Hematology/ Hematologic Malignancies  • Leukemias/ Lymphomas  • Immunologic Disorders  • Randomized Controlled Trial  • Alert me on articles by topic

Arch Dermatol. 2001;137:649-652.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

MYCOSIS FUNGOIDES is the most common form of cutaneous T-cell lymphoma (CTCL), which is in turn the most common adult non-Hodgkin T-cell lymphoma. This group of malignancies all involve infiltration of the skin by transformed T cells. When the correct diagnosis is made in stage IA disease, several treatments are available, each of which may arrest the progression of this disease. These treatments include potent topical steroids, various types of phototherapy, topical chemotherapy, and total-skin electron beam therapy. Regardless of treatment modality, the survival of patients with stage IA disease is comparable with that of age-matched controls. However, when the diagnosis is made in later stages (eg, higher than stage II), long-term survival is compromised. Current treatments for CTCL are effective primarily when disease is limited to the skin; therapies for disease that involves the lymph nodes, peripheral blood, and other organs is largely palliative. Chemotherapy for advanced disease has . . . [Full Text of this Article]

HOW DO REXINOIDS WORK?


HOW MIGHT REXINOIDS WORK IN CTCL?

MECHANISMS OF REXINOID TOXIC EFFECTS

COMMENT

RELATED ARTICLE

Phase 2 and 3 Clinical Trial of Oral Bexarotene (Targretin Capsules) for the Treatment of Refractory or Persistent Early-Stage Cutaneous T-Cell Lymphoma
Madeleine Duvic, Ann G. Martin, Youn Kim, Elise Olsen, Gary S. Wood, Constance A. Crowley, Richard C. Yocum, and for the Worldwide Bexarotene Study Group
Arch Dermatol. 2001;137(5):581-593.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

p21WAF1/CIP1 Is a Common Transcriptional Target of Retinoid Receptors: PLEIOTROPIC REGULATORY MECHANISM THROUGH RETINOIC ACID RECEPTOR (RAR)/RETINOID X RECEPTOR (RXR) HETERODIMER AND RXR/RXR HOMODIMER
Tanaka et al.
J. Biol. Chem. 2007;282:29987-29997.
ABSTRACT | FULL TEXT  

Biological Effects of Bexarotene in Cutaneous T-Cell Lymphoma
Budgin et al.
Arch Dermatol 2005;141:315-320.
ABSTRACT | FULL TEXT  

The Pathogenesis of Mycosis Fungoides
Girardi et al.
NEJM 2004;350:1978-1988.
FULL TEXT  

Psoralen Plus Long-Wave UV-A (PUVA) and Bexarotene Therapy: An Effective and Synergistic Combined Adjunct to Therapy for Patients With Advanced Cutaneous T-Cell Lymphoma
McGinnis et al.
Arch Dermatol 2003;139:771-775.
ABSTRACT | FULL TEXT  

Phase 1 and 2 Trial of Bexarotene Gel for Skin-Directed Treatment of Patients With Cutaneous T-Cell Lymphoma
Breneman et al.
Arch Dermatol 2002;138:325-332.
ABSTRACT | FULL TEXT  

Bexarotene Gel: A Food and Drug Administration-Approved Skin-Directed Therapy for Early-Stage Cutaneous T-Cell Lymphoma
Liu and Kim
Arch Dermatol 2002;138:398-399.
FULL TEXT